LGALS1 and Patent ductus arteriosus: In addition, using a combination of Gal1 and CA19-9 markers decreases the ratio of false-negatives and increases sensitivity and specificity, suggesting that Gal1 could be used as a complementary plasma biomarker for PDA diagnosis [59].